These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20732553)

  • 1. Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery.
    Mahla E; Metzler H; Tantry US; Gurbel PA
    Ann Thorac Surg; 2010 Sep; 90(3):1040-51. PubMed ID: 20732553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
    Tanguay JF; Bell AD; Ackman ML; Bauer RD; Cartier R; Chan WS; Douketis J; Roussin A; Schnell G; Verma S; Wong G; Mehta SR;
    Can J Cardiol; 2013 Nov; 29(11):1334-45. PubMed ID: 23978596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prasugrel: Clinical development and therapeutic application.
    Guerra DR; Tcheng JE
    Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
    Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E;
    Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
    Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.
    Islam AM; Patel PM
    J Cardiovasc Pharmacol; 2010 Jun; 55(6):585-94. PubMed ID: 20224426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin and clopidogrel resistance: consideration and management.
    Gurbel PA; Tantry US
    J Interv Cardiol; 2006 Oct; 19(5):439-48. PubMed ID: 17020569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST).
    Dewilde W; Berg JT
    Am Heart J; 2009 Nov; 158(5):713-8. PubMed ID: 19853687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability in responsiveness to oral antiplatelet therapy.
    Angiolillo DJ
    Am J Cardiol; 2009 Feb; 103(3 Suppl):27A-34A. PubMed ID: 19166710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions.
    Lepäntalo A; Virtanen KS; Heikkilä J; Wartiovaara U; Lassila R
    Eur Heart J; 2004 Mar; 25(6):476-83. PubMed ID: 15039127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
    Wiviott SD
    Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in oral antiplatelet therapy: ST-segment elevation myocardial infarction.
    Dauerman HL
    Am J Cardiol; 2009 Sep; 104(5 Suppl):39C-43C. PubMed ID: 19695360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
    Fox KA; Mehta SR; Peters R; Zhao F; Lakkis N; Gersh BJ; Yusuf S;
    Circulation; 2004 Sep; 110(10):1202-8. PubMed ID: 15313956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting.
    Shennib H; Endo M; Benhameid O
    Heart Surg Forum; 2003; 6(5):288-91. PubMed ID: 14721795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Capranzano P; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):361-9. PubMed ID: 19379060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticlopidine and aspirin therapy following implantation of coronary artery stents.
    Hobson AG; Sowinski KM
    Ann Pharmacother; 1997 Jun; 31(6):770-2. PubMed ID: 9184720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prasugrel development - claims and achievements.
    Serebruany V; Shalito I; Kopyleva O
    Thromb Haemost; 2009 Jan; 101(1):14-22. PubMed ID: 19132184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery.
    Cannon CP; Mehta SR; Aranki SF
    Ann Thorac Surg; 2005 Aug; 80(2):768-79. PubMed ID: 16039260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.